Dermatological Adverse Events Associated with Topical Brimonidine Gel 0.33% in Subjects with Erythema of Rosacea: A Retrospective Review of Clinical Studies

Background: The topical α2 adrenergic receptor agonist brimonidine gel 0.33% is an effective and safe pharmacological treatment for the facial erythema of rosacea. However, adverse events of worsened redness have occasionally been reported with its use. Objective: A detailed analysis of adverse even...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:J Clin Aesthet Dermatol
Main Authors: Holmes, Anna D., Waite, Kimberly A., Chen, Michael C., Palaniswamy, Kiruthi, Wiser, Thomas H., Draelos, Zoe D., Rafal, Elyse S., Werschler, W. Philip, Harvey, Alison E.
Formato: Artigo
Idioma:Inglês
Publicado: Matrix Medical Communications 2015
Assuntos:
Retrospective Review
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4557848/
https://ncbi.nlm.nih.gov/pubmed/26345379
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares